Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ROEL QUERUBIN

Allopathic & Osteopathic Physicians Internal Medicine Rheumatology

NPI
1124154323
CMS profile
278273
Location
MARIETTA, GA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$1,936.93

124 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,936.93 124

By paying entity

PY2020 · entire year · sorted by reported total

Page 3 of 3; records 101–124 of 124 matching records. This page contains 24 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ROEL QUERUBIN

NPI 1124154323 · CMS profile ID 278273

Allopathic & Osteopathic Physicians / Internal Medicine / Rheumatology

MARIETTA, GA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–124 of 124 matching records. This page contains 24 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1124154323?year=2020&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ROEL QUERUBIN, NPI 1124154323, CMS profile ID 278273. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–124 of 124 matching records. This page contains 24 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1124154323?year=2020&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). ROEL QUERUBIN, NPI 1124154323, CMS profile ID 278273. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–124 of 124 matching records. This page contains 24 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1124154323?year=2020&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
ROEL QUERUBIN, NPI 1124154323, CMS profile ID 278273, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–124 of 124 matching records. This page contains 24 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1124154323?year=2020&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

124 matching records · $1,936.93 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 124 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–124 of 124.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AbbVie Inc. $14.1602/11/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 722084269 CMS
Genentech USA, Inc. $16.1102/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743096111 CMS
Novartis Pharmaceuticals Corporation $19.1202/06/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 726089269 CMS
Amgen Inc. $20.2702/05/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 741436745 CMS
Antares Pharma, Inc. $15.4002/05/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751418425 CMS
Amgen Inc. $3.6002/04/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 741436743 CMS
Horizon Therapeutics plc $15.7202/03/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 721433881 CMS
AbbVie Inc. $17.5401/29/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 722084263 CMS
AbbVie Inc. $1.0701/29/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 722084265 CMS
MEDEXUS PHARMA, INC. $13.2101/23/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 749895341 CMS
Horizon Therapeutics plc $21.7601/22/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 721433879 CMS
Novartis Pharmaceuticals Corporation $23.7401/21/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 726089267 CMS
SANOFI-AVENTIS U.S. LLC $22.8101/20/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744162445 CMS
PFIZER INC. $17.9101/16/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743060736 CMS
AbbVie Inc. $24.5801/15/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 722084261 CMS
Horizon Therapeutics plc $11.5201/14/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 721433877 CMS
Radius Health, Inc. $12.2501/14/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 746305609 CMS
Amgen Inc. $12.4801/09/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 741290189 CMS
Novartis Pharmaceuticals Corporation $7.5801/09/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 726089263 CMS
E.R. Squibb & Sons, L.L.C. $14.4701/08/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 727821431 CMS
AbbVie Inc. $1.6801/07/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 722084259 CMS
Amgen Inc. $24.2401/07/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 741290211 CMS
AbbVie Inc. $19.3901/06/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 722084257 CMS
Janssen Biotech, Inc. $14.2301/02/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719390377 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $3,765.45 213
PY2020 $1,936.93 124
PY2021 $2,250.94 133
PY2022 $3,071.44 182
PY2023 $4,243.37 226
PY2024 $4,669.55 227
PY2025 $4,512.97 234

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $377,962.29 41
PY2024 Recipient $114.46 1
PY2024 Principal investigator $401,977.94 43
PY2023 Principal investigator $218,427.52 29
PY2022 Principal investigator $97,151.73 49
PY2021 Recipient $16.15 1
PY2021 Principal investigator $194,091.85 47
PY2020 Principal investigator $117,660.95 38
PY2019 Principal investigator $88,382.60 18

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

41 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $2,077.30 12/04/2025 Non-covered Recipient Entity
ATLANTA RESEARCH CENTER FOR
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202527574
Principal investigator 1 ABBVIE INC. $192.10 12/04/2025 Non-covered Recipient Entity
ATLANTA RESEARCH CENTER FOR
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202527576
Principal investigator 1 GlaxoSmithKline, LLC. $11,556.90 11/05/2025 Non-covered Recipient Entity
ATLANTA RESEARCH CENTER FOR RHEUMATOLOGY
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192098093
Principal investigator 1 ABBVIE INC. $3,176.50 11/04/2025 Non-covered Recipient Entity
ATLANTA RESEARCH CENTER FOR
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202520285
Principal investigator 1 GlaxoSmithKline, LLC. $2,600.00 10/28/2025 Non-covered Recipient Entity
ATLANTA RESEARCH CENTER FOR RHEUMATOLOGY
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192150880
Principal investigator 1 Eli Lilly and Company $16,380.00 10/21/2025 Non-covered Recipient Entity
ATLANTA RESEARCH CENTER FOR
A PHASE 4, PROSPECTIVE, OPEN-LABEL, SINGLE-ARM STUDY TO ASSESS THE EFFECTIVENESS OF TIRZEPATIDE AFTER INITIATION OF IXEKIZUMAB IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OVERWEIGHT OR OBESITY IN CLINICAL PRACTICE No dispute reported 06/30/2026 1187875993
Principal investigator 1 GlaxoSmithKline, LLC. $4,823.10 10/02/2025 Non-covered Recipient Entity
ATLANTA RESEARCH CENTER FOR RHEUMATOLOGY
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192150858
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $10,020.00 09/24/2025 Non-covered Recipient Entity
ATLANTA RESEARCH CENTER FOR RHEUMATOLOGY LLC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223285852
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,040.00 09/24/2025 Non-covered Recipient Entity
ATLANTA RESEARCH CENTER FOR RHEUMATOLOGY LLC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223285854
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $937.50 09/24/2025 Non-covered Recipient Entity
ATLANTA RESEARCH CENTER FOR RHEUMATOLOGY LLC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223285856
Principal investigator 1 GlaxoSmithKline, LLC. $2,150.00 09/10/2025 Non-covered Recipient Entity
ATLANTA RESEARCH CENTER FOR RHEUMATOLOGY
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192098081
Principal investigator 1 GlaxoSmithKline, LLC. $2,000.00 09/10/2025 Non-covered Recipient Entity
ATLANTA RESEARCH CENTER FOR RHEUMATOLOGY
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192150874
Principal investigator 1 ABBVIE INC. $2,027.30 09/03/2025 Non-covered Recipient Entity
ATLANTA RESEARCH CENTER FOR
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202507301
Principal investigator 1 GlaxoSmithKline, LLC. $0.90 09/03/2025 Non-covered Recipient Entity
ATLANTA RESEARCH CENTER FOR RHEUMATOLOGY
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192150855
Principal investigator 1 ABBVIE INC. $2,615.00 08/05/2025 Non-covered Recipient Entity
ATLANTA RESEARCH CENTER FOR
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202501420
Principal investigator 1 ABBVIE INC. $2,353.00 08/05/2025 Non-covered Recipient Entity
ATLANTA RESEARCH CENTER FOR
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202501466
Principal investigator 1 GlaxoSmithKline, LLC. $3,170.70 08/01/2025 Non-covered Recipient Entity
ATLANTA RESEARCH CENTER FOR RHEUMATOLOGY
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192150883
Principal investigator 1 ABBVIE INC. $7,473.70 07/02/2025 Non-covered Recipient Entity
ATLANTA RESEARCH CENTER FOR
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202494485
Principal investigator 1 GlaxoSmithKline, LLC. $2,405.70 07/02/2025 Non-covered Recipient Entity
ATLANTA RESEARCH CENTER FOR RHEUMATOLOGY
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192150862
Principal investigator 1 GlaxoSmithKline, LLC. $3,649.50 06/04/2025 Non-covered Recipient Entity
ATLANTA RESEARCH CENTER FOR RHEUMATOLOGY
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192150870
Principal investigator 1 GlaxoSmithKline, LLC. $6,044.40 05/09/2025 Non-covered Recipient Entity
ATLANTA RESEARCH CENTER FOR RHEUMATOLOGY
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192098087
Principal investigator 1 ABBVIE INC. $1,139.70 05/07/2025 Non-covered Recipient Entity
ATLANTA RESEARCH CENTER FOR
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202482703
Principal investigator 1 ABBVIE INC. $4,256.20 05/06/2025 Non-covered Recipient Entity
ATLANTA RESEARCH CENTER FOR
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202481399
Principal investigator 1 ABBVIE INC. $2,152.80 04/03/2025 Non-covered Recipient Entity
ATLANTA RESEARCH CENTER FOR
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202471451
Principal investigator 1 ABBVIE INC. $1,139.70 04/03/2025 Non-covered Recipient Entity
ATLANTA RESEARCH CENTER FOR
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202471459
Principal investigator 1 GlaxoSmithKline, LLC. $5,564.70 04/02/2025 Non-covered Recipient Entity
ATLANTA RESEARCH CENTER FOR RHEUMATOLOGY
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192151442
Principal investigator 1 UCB SA $11,550.00 03/27/2025 Non-covered Recipient Entity
ATLANTA RESEARCH CENTER FOR RHEUMATOLOGY LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DAPIROLIZUMAB PEGOL IN STUDY PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS No dispute reported 06/30/2026 1246657714
Principal investigator 1 ABBVIE INC. $4,741.60 03/07/2025 Non-covered Recipient Entity
ATLANTA RESEARCH CENTER FOR
M23-700 - Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202459702
Principal investigator 1 ABBVIE INC. $2,278.90 03/07/2025 Non-covered Recipient Entity
ATLANTA RESEARCH CENTER FOR
M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202459706
Principal investigator 1 GlaxoSmithKline, LLC. $5,810.40 03/07/2025 Non-covered Recipient Entity
ATLANTA RESEARCH CENTER FOR RHEUMATOLOGY
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192151438
Principal investigator 1 UCB SA $719.98 03/05/2025 Non-covered Recipient Entity
ATLANTA CENTER FOR CLINICAL RESEARCH
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DAPIROLIZUMAB PEGOL IN STUDY PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS No dispute reported 06/30/2026 1246657706
Principal investigator 1 ABBVIE INC. $4,677.00 02/06/2025 Non-covered Recipient Entity
ATLANTA RESEARCH CENTER FOR
M23-700 - Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202446972
Principal investigator 1 ABBVIE INC. $1,977.30 02/06/2025 Non-covered Recipient Entity
ATLANTA RESEARCH CENTER FOR
M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202446995
Principal investigator 1 GlaxoSmithKline, LLC. $33,945.30 02/05/2025 Non-covered Recipient Entity
ATLANTA RESEARCH CENTER FOR RHEUMATOLOGY
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192150866
Principal investigator 1 Eli Lilly and Company $84,351.00 01/28/2025 Non-covered Recipient Entity
ATLANTA RESEARCH CENTER FOR
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) No dispute reported 06/30/2026 1187875277
Principal investigator 1 UCB SA $3,480.00 01/28/2025 Non-covered Recipient Entity
Marietta Rheumatology Associates, Pc
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DAPIROLIZUMAB PEGOL IN STUDY PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS No dispute reported 06/30/2026 1246657488
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $104,337.22 01/21/2025 Non-covered Recipient Entity
Atlanta Research Center For Rheumatology
A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (POETYK SLE-2) No dispute reported 06/30/2026 1235998842
Principal investigator 1 GlaxoSmithKline, LLC. $9,910.00 01/17/2025 Non-covered Recipient Entity
ATLANTA RESEARCH CENTER FOR RHEUMATOLOGY
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192151445
Principal investigator 1 Eli Lilly and Company $2,017.19 01/08/2025 Non-covered Recipient Entity
ATLANTA RESEARCH CENTER FOR
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) No dispute reported 06/30/2026 1187877125
Principal investigator 1 ABBVIE INC. $1,672.30 01/02/2025 Non-covered Recipient Entity
ATLANTA RESEARCH CENTER FOR
M23-700 - Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202433546
Principal investigator 1 ABBVIE INC. $4,547.40 01/02/2025 Non-covered Recipient Entity
ATLANTA RESEARCH CENTER FOR
M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202433566